[artículo]
| Título : |
Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder : randomized double-blind placebo-controlled trial |
| Tipo de documento: |
texto impreso |
| Autores: |
Carlos M. Grilo, Autor ; Janet A. Lydecker, Autor ; Sarah K. Fineberg, Autor |
| Fecha de publicación: |
2023 |
| Artículo en la página: |
pp. 927-937 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Obesidad, Trastornos de la alimentación, Trastornos de la alimentación, Alimentación, Trastorno por atracón, Pérdida de peso, Farmacoterapia, Combinación de drogas, Psicoterapia, Terapia de comportamiento. |
| Resumen: |
Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments. Binge-eating disorder remains underrecognized and infrequently treated, and few evidence-based treatments exist. The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity. |
| Link: |
./index.php?lvl=notice_display&id=29782 |
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 12 (Diciembre) . - pp. 927-937
[artículo] Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder : randomized double-blind placebo-controlled trial [texto impreso] / Carlos M. Grilo, Autor ; Janet A. Lydecker, Autor ; Sarah K. Fineberg, Autor . - 2023 . - pp. 927-937. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 12 (Diciembre) . - pp. 927-937
| Palabras clave: |
Obesidad, Trastornos de la alimentación, Trastornos de la alimentación, Alimentación, Trastorno por atracón, Pérdida de peso, Farmacoterapia, Combinación de drogas, Psicoterapia, Terapia de comportamiento. |
| Resumen: |
Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments. Binge-eating disorder remains underrecognized and infrequently treated, and few evidence-based treatments exist. The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity. |
| Link: |
./index.php?lvl=notice_display&id=29782 |
|
Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder en The American Journal of Psychiatry, Año 2022 - Vol. 179 - No. 12 (Diciembre)
